1971 636

Cited 0 times in

Duchenne 근디스트로피의 치료에 대한 고찰

DC Field Value Language
dc.contributor.author박형준-
dc.contributor.author최영철-
dc.date.accessioned2014-12-19T17:54:06Z-
dc.date.available2014-12-19T17:54:06Z-
dc.date.issued2012-
dc.identifier.issn1225-7044-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/92271-
dc.description.abstractDuchenne muscular dystrophy (DMD) is an X-linked recessive disorder due to the loss of dystrophin in muscle fiber. The deficiency of dystrophin produces severe progressive muscle degeneration which leads to progressive muscle weakness. Affected patients usually become unambulatory in their early teens, and suffer a respiratory failure before 20 years of age. In an attempt to improve quality of life and extend life span of DMD patients, various treatments have been challenged; corticosteroid trial, rehabilitation, cardiac and pulmonary managements, orthopedic interventions, and nutritional support. However, only corticosteroid therapy and non-invasive ventilation have shown a salutary effect on the clinical course of DMD. Recently, a better understanding of the DMD pathophysiology has provided the scientific basis for new treatment modalities including cell and molecular therapy. Although previous clinical trials have demonstrated the limitation and possibility of new therapies, antisense-mediated exon skipping technology is now emerging as a promising approach to restore dystrophin expression. This article summarizes the current challenges and recommendations of treatment approaches in DMD patients.-
dc.description.statementOfResponsibilityopen-
dc.relation.isPartOfJournal of the Korean Neurological Association-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleDuchenne 근디스트로피의 치료에 대한 고찰-
dc.title.alternativeTreatment of Duchenne Muscular Dystrophy: A Comprehensive Review-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Neurology (신경과학)-
dc.contributor.googleauthor박형준-
dc.contributor.googleauthor최영철-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01758-
dc.contributor.localIdA04116-
dc.relation.journalcodeJ01835-
dc.identifier.pmidCell therapy ; Corticosteroids ; Duchenne muscular dystrophy ; Gene therapy-
dc.subject.keywordCell therapy-
dc.subject.keywordCorticosteroids-
dc.subject.keywordDuchenne muscular dystrophy-
dc.subject.keywordGene therapy-
dc.contributor.alternativeNamePark, Hyung Jun-
dc.contributor.alternativeNameChoi, Young Chul-
dc.contributor.affiliatedAuthorPark, Hyung Jun-
dc.contributor.affiliatedAuthorChoi, Young Chul-
dc.citation.volume30-
dc.citation.number4-
dc.citation.startPage257-
dc.citation.endPage266-
dc.identifier.bibliographicCitationJournal of the Korean Neurological Association, Vol.30(4) : 257-266, 2012-
dc.identifier.rimsid29374-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Neurology (신경과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.